Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantl

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Maximum Tolerated Dose of Vorinostat

Source null

→

primary · POSTED

Common dose limiting toxicities.

Source null

→

primary · POSTED

Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy

Source null

→

primary · POSTED

Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id: NCT00601718
trial label: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantl
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 4
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0000
source section id
NCT00601718-om-0000
source outcome index
0
endpoint
Maximum Tolerated Dose of Vorinostat
endpoint definition
Maximum Tolerated Dose of Vorinostat
time origin
28 days post last dose of study drug
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0001
source section id
NCT00601718-om-0001
source outcome index
1
endpoint
Safety and Toxicity According to CTCAE v3.0
endpoint definition
Common dose limiting toxicities.
time origin
3-5 weeks post end of treatment
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0002
source section id
NCT00601718-om-0002
source outcome index
2
endpoint
Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy
endpoint definition
Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy
time origin
3-5 weeks post end of treatment
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0003
source section id
NCT00601718-om-0003
source outcome index
3
endpoint
Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment
endpoint definition
Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment
time origin
1-3 weeks post end of treatment
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0000
arm key
OG000
arm label
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
regimen
Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
analyzed count
29
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00601718-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0001
arm key
OG000
arm label
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
regimen
Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
analyzed count
29
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00601718-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0002
arm key
OG000
arm label
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
regimen
Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
analyzed count
29
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00601718-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
outcome key
om-0003
arm key
OG000
arm label
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
regimen
Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
analyzed count
21
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00601718-om-0003#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00601718
harm key
EG000
source section id
NCT00601718-ae
event group key
EG000
event group label
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
serious affected
10
serious at risk
29
other affected
25
other at risk
29
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice